Granzyme B imaging uses a radioactive tracer to study an enzyme released by cytotoxic immune cells. Early studies show feasibility and response associations; they do not validate choosing or stopping treatment from a scan.
Granzyme B is an enzyme released by cytotoxic T cells and natural killer cells. Experimental PET tracers use labelled peptides or peptidomimetics to target granzyme-associated activity. This is distinct from CD8 antibody-derived binder imaging and does not by itself establish recognition of a particular tumour antigen, identify which cell released the enzyme or prove a durable response.
Larimer's 2017 proof of concept used mouse models and examined human biopsy specimens; it was not a human PET trial. A 2026 review describes 68Ga and 18F tracer approaches and early human feasibility while noting standardisation and validation needs. In Shen's 2024 phase 1/2 study, 68Ga-grazytracer imaging in 24 patients with mixed solid tumours or lymphomas explored distribution, safety and response associations after immune treatment. It did not randomise a scan-guided treatment strategy.
A positron-emitting label on a peptide or peptidomimetic enables imaging of its granzyme-associated distribution; tracer chemistry, timing, access and background affect interpretation.
Query for this technology: (TITLE:"Granzyme B PET" OR ABSTRACT:"Granzyme B PET" OR TITLE:"Granzyme-B PET" OR ABSTRACT:"Granzyme-B PET" OR TITLE:"Granzyme B molecular imaging" OR ABSTRACT:"Granzyme B molecular imaging") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Granzyme B PET, not a curated reading list.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/